newsfilter
← Latest News
Earnings Call Transcripts·

Metagenomi Therapeutics, Inc. at Jefferies Global Healthcare Conference in London - METAGENOMI THERAPEUTICS INC

Hi, everyone. My name is Maury Ray Crofton, one of the biotech analysts at Jefferies. I'd like to welcome the team from Metagenome. We've got the CEO, John Irish, and the CFO, Pamela Wapnick. Thanks so much for joining us today. Metagenomy is going to show some slides, and then we'll do a fireside chat format. Thank you very much, Maury. I'm pleased to be here. So we'll start with a short presentation, show our data. So MetaGerm is an in vivo CRISPR gene editing company, so we capitalize on proprietary technologies to create potentially creative genetic medicines. We recently cleared IND for our lead program, MGX001, with a novel approach for hemophilia A. So we're focused on initiating the Phase I-II study in the first half of next year. So this is our forward-looking statement. So let me begin by briefly telling you about hemophilia A. So children with severe hemophilia A today still grow up expecting joint damage from the cumulative bleeding disorder, despite the real progress in managing the disease. The patient population is significant as a rare disease. There are about 500,000 patients worldwide and 25,000 patients in the U.S. One-third of the patients have no family history, so a newly diagnosed patient and his family would have to spend a long time learning to manage bleeding and treatment burdens that would last for the rest of life. So we plan to initiate an integrated aid phase 1-2 trial in adult patients with moderately severe to severe hemophilia A with the future potential to expand it to children. So what I want to tell you, the totality of our preclinical data is extremely convincing, supports a highly differentiated profile with the potential to set a new standard of care. So now let's talk about the standard of a care landscape. So factor VIII replacement and non-factor VIII mimetic treatments require lifelong, repeated dosing. And it is non-curative, still has a risk of a breakthrough bleeding. So those treatments also come with extraordinary cost. What you see here are just the treatment costs. So then the recent trial with the AAV gene therapy for one-time treatment was initially promising but experienced limited uptake in the market, mostly attributed to unpredictable and a decline in factor VIII activity over the time. Of course, prolonged steroid use also presented a treatment challenge. we see the opportunity to develop a genuine, durable, one-time treatment to address the root genetic cause and provide a long-term benefit for both adults and especially children who have the most to benefit from a one-term treatment. So our gene editing approach is structurally different from the prior AAV gene therapy. And rather than remain epizomal, the FACT-8 gene integrates directly into the chromosomal targeting the stable and active albumin promoter. So we deliver a promoterless FACT8 DNA template. I should say we deliver FACT 8 DNA template in a promoteless AAV cassette. and we also deliver the LNP encapsulate to the mRNA that encodes our proprietary CRISPR nucleus, MG291, and the guide. That integrates the fact-aided gene site-specifically at the albumin loci locus to drive sustained fact-aid production with durable and high expression with very low gene integration frequency. Now I want to show you some data from our preclinical study. So durability is most important for one-time treatment, and we consider this very early in our development and early study done in the NHP model. We use a research version of a pre-development candidate. We saw the rise of the factor VIII to the peak level activity within two weeks and remained stable through the end of a study up to 19 months. Most importantly is the factor VIII activity is correlated to the integration frequency. And we also saw stable factor VII expression was achieved in the study that animals' liver size doubled over the duration of the study, which is exactly what you'd expect given our mechanism, since the editing becomes a permanent part of a genome rather than epizomal expression that could fade over time. The second important study was the dose range finding study. We are extremely pleased by the clear dose dependency in this study, and especially with the FACT-8 activity level reaching the normal physiological range of 50 to 150 IU per deciliter in the target group 2 and 5 shown in the dark blue. That is our target range. Now, if you consider severe hemophilia patients only has less than 1% IU per deciliter factor 8 level, this could be a significantly drastic clinical meaningful shift. also important is the animals in the study did not exceed the ceiling expression level 150 IU per decilitre that could increase the risk of cirrhosis even at the highest dose levels and we see this as a potential wide safety margin in our design and then you also look at the minimal dose in group cohort group 1, we've already reached 10 to 25 IU per deciliter. That is the level of the current memetic standard of care would achieve in equivalency. Just to remember, memetics don't express FACT-8, but it's the equivalency of the activity level. I want to point out the AAV dose level we use in this study that achieved normal range factor A, the activity level is very low. It's roughly, it's more than actually tenfold below the previous AAV gene therapy, which we believe is an important safety factor in clinic. So now we have the IAD clearance that enables us to initiate our Phase I-II clinical trial in the U.S., and we plan to submit applications in additional regulatory jurisdictions to support our global trial. We plan, we're focused on initiating our study in the first half of next year, expected to share initial clinical data in the second half. Finally, I want to leave this with you as we consider the follow-on programs. The MGX001G integration approach by delivering the Factor VIII template with AAV and CRISPR gene editing cargo in the LNP is a modular system. We can replace the therapeutic transgene DNA template to expand into other protein deficiencies and diseases and expected to gain development efficiency. So with that, I'm happy to take any questions. Great. Thanks, Jian. That was a nice intro to the company and where you're at, and congrats on the IND clearance. Maybe just starting with just kind of one of the common things that we hear is that for hemophilia, hemophili-A, that's a well-served disease setting where there are a lot of great treatments out there, as you engage with the hemophilia community what specific feedback have you gotten and how has that informed your clinical development strategy that is very important question so we have engaged with hemophiliac community very early and use the feedback to guide our development the path so what we have learned is it's very clear the current standard of care is just to manage the diseases but not address the genetic root causes and patients still have to you know have to experience the breakthrough um bleedings and restricted lifestyles and surgery and injury risks diseases always on their mind right they have to adjust their lifestyle to manage the diseases um then we also learned from uh the hematologists that there is just undetectable microbleeds that could lead to atheropathy. Even the best physicians with the best treatment, they still have to advise the patients or the parents of the patients that they cannot eliminate the atheraphy in the later in their life. So factor VIII level has the half-life so that it goes to peaks and trough and memetics really don't express factor VVIII. So the microbleed in risk in the late life is still not clear. And you also saw, in addition to treatment of burdens, there's a cost of burdens and the burdens of dealing with reimbursement. So from patients' perspective, this is truly a medical need to them. And our goal is to deliver one-time treatment to normalize the factor VIII levels and really giving the disease-free mind to the patients. That makes sense. And you basically talked about one patient population opportunity right there where those patients would likely go for a one-time treatment, older patients that have the microbleeds, which is interesting. And so now that the IND is cleared, can you give us a sense of the remaining operational steps to first dosing and the higher thinking about timing there? And what first patient dose window would keep you comfortable with a meaningful update in second half of 27? So first I'll just talk about the study. So the Phase I-II study we named as Integrate Clinical Trial is open-label, single-arm, and we're going to use multiple centers, including international centers, for this study. And then with dose escalation followed by dose expansion, we reached the target efficacy level. So our target efficacy level is the normal physiological level. It's at 50% to 150%. And as I said, severe patients only have less than 1%, so it is a really significant shift for the patients. Then the second is we have got IND in the U.S., so multi-center including outside of U.N. treatment centers. We work with the major centers that have experience in the gene therapy for hemophilia treatments in the past. And also important is those sites, including, of course, Europe, as well as other countries that advance the standard of care is not available. Then I also want to just characterize this as important of our learning from the community is that typically for hemophilia patients, the hematologists, they follow the patients for their lifetime. So they know the patients, they know the patient population who's looking for one-time treatment, especially the patients who are still in the active life phase, have the most strong desire. Then, of course, we have clinical supply ready, and it's all released, ready to go. So we're really focusing on to get the study initiated the first half of next year. Got it. And that's all helpful. And then I guess for getting to data in the second half of next year, maybe talk about what that could look like, how many patients you could have in that data update. So, of course, we started with the lower dose but with biological activities. So we were escalated. Another important point I want to mention to you is on the early slide, you saw, the rise of FACT-8 activity within two weeks is really important for us to take that into consideration. So for the initial study, we're not only going to observe the safety signals, but also activity levels. In terms of the number of patients per cohort, we'll follow the standard phase one until we reach the target efficacy level and for expansion. We do expect to see activities in the initial patient groups and make decisions to escalate to our target and efficacy. Got it. And just clarifying, so for the LNP versus AAV, so would you increase the dose of the LMP and keep the AAV dose constant? Yeah, the dose range of finding study was really clear. when we fixed the AAV dose, we just saw a linear correlation with the efficacy as we escalated the LMP. So we plan to follow that approach. What's really nice about this is the AAVE dose is low, as I talked about, but even with LMP we saw the activity level at the standard of care level at a very low LMP dose, like 0.2 milligrams. So we do expect we'll get really good signals on not only safety and activities at the beginning. And this also simplifies the clinical trial design. Right. Yeah, it makes sense. And how do you view the overall safety profile and do you need to implement any unique risk mitigation measures for the study? The answer is no. Because our preclinical study showed a really good favorable clinical safety profile. We only saw mild transit liver enzyme elevation for the targeted dose cohorts. So we will implement a short course of pre-medication before the LNP dose, but other than that, we do not expect. We're going to see safety signals from the Phase I study initial patients, And, of course, we're going to monitor closely, and if there's a need for adjustment, we'll adopt to that. And it's really good as we're working with the hematologists who are experienced with gene therapy. So it will be a really good collaboration. Is that pre-medication regimen? Is that already determined, or are there still some variables there? It will agree with the FDA. Got it. Okay. And is there anything more you can say about what it is? Is it steroids? It would be a very, yeah, it would be a steroid course. It's very simple and nothing unfamiliar from what you have seen in the CRISPR. Yeah, a short steroid class. Got it. Okay. And presumably dosing is going to be staggered between patients in the initial cohorts. What is FDA's guidance for a safety observation window before dosing the next patient? And when in development could you get to non-staggered or concurrent dosing yeah um i want to say um the phase one study has observation of safety and activities right so if we see the activities start to rise within two weeks you know we'll see the safety and activities almost at the same time and then we make decisions on the patient enrollment based upon what we see of the both elements um because we started at a very low dose I think we feel pretty good about the balance of the two arms as we escalate the dose cohorts. One more thing I think it's important to remember is we already set up our targeted dose at a normal physiological range, so we'll be efficient as we accelerate towards that dose level so long as we don't see concerning safety. seeing those. Got it. Okay. And so, yeah, as you're going to higher doses, we can assume that you've got safety, but you're probably also seeing efficacy as well. I guess once you hit efficacy, then does that lead to an expansion? Exactly. Yeah. Okay, but Maury, just to clarify, we expect to see efficacy even with our initial dose, right? And that could be at the level that is comparable to the current standard of care when you think about what we saw in non-human primates. So if you just did a one-to-one translation from non-human primates to humans, you would be at kind of the current standard of care level. Got it. Makes sense. And talk about your LNP. How differentiated is your LMP from clinically validated formulations? Are the key lipids proprietary or licensed? And is there direct human exposure to the same components? We use a licensed lipid that adapted to our CRISPR gene editing cargo. Average cargo is different. So we have already shown the effectiveness of that. And the lipid has been used in the clinic, and that is ahead of us. Got it. And so maybe set the stage for what the first data update is going to look like. What benchmarks are going to define a positive outcome for you? Is it primarily the biomarker, or could we also see some functional improvement measures as well? Absolutely. I think we touched upon in the early points where we'll see activities. I think what Pam made a point is important and just to look at all the CRISPR gene editing programs and we see the translation from animal models to human is highly efficient and the efficacy is looking better than the doses used in the animals. So we're already seeing the low dose activities and low dose within that translation. would be very key for us to watch out. Got it. And what minimum percent editing efficiency do you predict you'll need to achieve for durable therapeutic benefit? And will you do any exploratory biopsies to assess editing efficiency? So I want to just make a distinction. I make sure I understand your question because our durability is driven by the mechanism of action. So we're not intending to drive high activities and then let it drop, right? Right. So we tested this in the growing juvenile monkeys in the NHP study. We also have done study to see the dividing cells will continue to have the stable factor in expression. So that is the most important for us. Once again, we're targeting the normal physiological range, and we've shown the durability data in the NHP that is as good as everybody could have hoped for. So, of course, we are going to show some additional data later in our ASH oral presentation in December. But in terms of biopsy, we use the standard protocol, which is optional for hemophilia treatments. Okay, so you could potentially get biopsies from some patients. Yeah, it's really up to the patient and the physicians. But for like an editing efficiency percentage, is there something on that that you're commenting on, on what the minimum amount of editing efficiency you'd want to see? The editing efficiency, yes. So once again, it is gene insertion. So what we measure with the data you have shown is the activity is really correlated in the factor 8 integration. and the integration is very, very low. So as we think about that, the editing in the term is more than just the CRISPR. You do the editing and one step, that's it done. So we have the integration. So we are measuring the outcome of the integration What we have learned is the activity from the integration and the translation is always correlated as we gain more sample data and we just get a more affirmed understanding of the translation. And we hope that's going to translate in humans as well. And just based upon mechanism of action, we really feel that's gonna work in the way, yeah. Got it. As we have shown. Yeah, yeah, it makes sense. which we see that with other gene editing programs, too, that are in vivo in the liver. You see the non-human primate editing translate to humans pretty directly, and you're pretty confident in that relationship between the editing and the factor VIII expression. That's correct, yes. And so you mentioned the ASH data that you're going to have in December. Your prior NHP data showed strong factor VII activity but some animal-to-animal variability. Do you understand the source of that variability and what evidence gives you confidence the product entering the clinic will deliver more consistent expression? Yeah. The two sets of data I've shown you today have shown, like, the range has been tightened over our development paths, right? The first study we've done was research material, and you saw more variability. But as we went on to the dose range finding studies, the range is getting tighter and tighter. In fact, the range we are targeting, 50 to 150, is a pretty broad range, whereas we're showing the animals within 30 io per decilit. So that's as good as you can get. So as we gain more samples, as we eventually will show more data at ASH, we just see that range getting tighter and tighter in reflecting the mechanism. Got it. Okay. And is there more you can share on OO1 timelines and strategy that can help investors better frame the investment thesis? What's the most likely registrational path, and when do you get registration data in-house? Once again, I want to say the factor 8 expression kinetics is very different from the epizomal gene therapy previously we have seen. So it's very distinctive. We see quick onset and fact-aid activity, and it remains stable. So once we see the initial patient data and showing that pattern, I think it will really give us some opportunities to engage the regulatory and have conversations on the further development path for the next phase. That makes sense. That's basically the gating factor. As far as timing of that goes, you're not saying a whole lot, but is it fair to assume that it could be around the second half of 27 data? I think the initial patient is going to tell us a lot. Yeah, okay. Okay, that's fair. And also briefly wanted to ask any Ionis partnership in place. You've disclosed three or four targets as part of Wave 1, including ATTR and AGT, and most recently APOC3 for SHTG. What's the status of these programs and anything more that you can say on timelines at this point? Yeah, we want to have him too. Yeah, so I'll maybe field that one for you, Maury. So we are really pleased with our relationship with IONIS. As you mentioned, there are four targets in the collaboration, and three of them have been named. One of them is not named. In terms of the original agreement with Ionis, it was for an $80 million upfront, and we had two options to opt in. But we do have to look to IONis for any further data that we can release about those programs. So, for example, a declaration of a development candidate is solely a decision of IONIs. Got it. Okay. And maybe just briefly talk about the distinct nuclease families you've identified and characterized to date and how many are actively being developed for therapeutic or partnership potential. Yeah, you'll just see the first case that we applied to 29.1 to this study. In fact, it's really uniquely strong, this nucleus, that we saw no off-target editing, no translocations. It's very clean gene editing profiles. And we also, of course, we have a vast library of technologies in the background. We are going to continue to pursue additional therapeutic programs with the gene integration platform and continue to expand our collaboration opportunities for other gene editing technologies, whether it's knockdown, whether it is insertion with multiplex editing or correction or compact nucleases. and it's all in our, you know, toolbox for physical collaboration. Got it. So we're out of time. Maybe to close out, if you want to highlight your cash runway assumptions and key catalysts ahead for the next 6 to 12 months. Yeah, sure. So at the end of September, we had about $102 million on the balance sheet, and that was sufficient for a runway through 2028. The key point being that in 2027, we anticipate some very significant milestones around our integrate clinical trial. That includes the initiation of the clinical trial in the first half and the initial clinical readout in the second half. And that clinical read out, as we've said, will include efficacy as well as safety and tolerability. We've mentioned that we're very excited to be on the podium at ASH, and I'll just close by saying that in a landscape with no cure for hemophilia A, we believe MGX001 has the potential to provide long-term benefit for both adults and children with hemopholia and to potentially change the standard of care. Got it John Pam. Thanks so much for joining us today

Company
METAGENOMI THERAPEUTICS INC
Keywords
METAGENOMI THERAPEUTICS INC